Zevra Therapeutics
ZVRA
38 hedge funds and large institutions have $14.6M invested in Zevra Therapeutics in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding
Funds holding: 38 → 38 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
11% less capital invested
Capital invested by funds: $16.5M → $14.6M (-$1.86M)
55% less call options, than puts
Call options by funds: $29K | Put options by funds: $64K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$176K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$173K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$168K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$167K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$99.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$741K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$459K |
| 3 |
CI
Cowen Inc
New York
|
-$294K |
| 4 |
JGC
J. Goldman & Co
New York
|
-$160K |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$97.1K |
ZVRA Hedge Fund Activity: Q1 2019 in Review
38 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2019, worth a combined $14.6M — down 11% from $16.5M a quarter earlier.
Fund positioning in ZVRA was balanced in Q1 2019: 6 funds opened new positions, 6 closed out, 10 added to existing stakes and 8 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $176K. The largest seller was Alyeska Investment Group, cutting an estimated $741K.
- 38 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $14.6M of Zevra Therapeutics stock for Q1 2019, down 11% quarter-over-quarter.
- 6 funds opened new Zevra Therapeutics positions in Q1 2019 and 6 closed out, a net change of 0 holders.
- The largest Zevra Therapeutics buyer in Q1 2019 was Susquehanna International Group, an estimated $176K added.
- The largest Zevra Therapeutics seller in Q1 2019 was Alyeska Investment Group, an estimated $741K sold.
Based on aggregated 13F filings for Q1 2019.